





%4a" HMD9G'C: 'B: 97 HCB'5 GGC7-5 H98' K #k: 71 @H F9fGL' f7\ YW' U''h UHidd'ntL
Abscess, not skin
AV fistula/graft infection
Bacteremia
Bursitis
Catheter site infection (CVC)
Cellulitis
Chronic ulcer/wound (not decubitus)
Decubitus/pressure ulcer
Empyema
Endocarditis
Epidural Abscess
Meningitis
Osteomyelitis
Peritonitis
Pneumonia
Pyelonephritis
Septic arthritis
Septic emboli
Septic shock
Skin abscess
Surgical incision infection
Surgical site infection (internal)
Traumatic wound
Urinary tract infection
Other (specify):

%8" I B89F @MB; '7 CB8 #HCBG: f7\ YW' U''h UHidd'ntL
7 <FCB7' @ B; '8 -G95 G9'
7 <FCB7' A9H56 C @7' 8 -G95 G9
7 5F8-CJ5G7I @F 8 -G95 G9'
; 5 GHFC-BH9GH5 @8 -G95 G9
HIV infection
AIDS/CD4 count < 200
Primary immunodeficiency
Transplant, hematopoietic stem cell
Transplant, solid organ
Chronic liver disease
Ascites
Cirrhosis
Hepatic encephalopathy
Variceal bleeding
Hepatitis C
Treated, in SVR
Current, chronic
Malignancy, hematologic
Malignancy, solid organ (non-metastatic)
Malignancy, solid organ (metastatic)
Cerebral palsy
Chronic cognitive deficit
Dementia
Epilepsy/seizure/seizure disorder
Multiple sclerosis
Neuropathy
Parkinson's disease
Other (specify):
Hemiplegia
Paraplegia
Quadriplegia
Chronic kidney disease
Lowest serum creatinine: mg/DL
Unknown or not done
Burn
Decubitus/pressure ulcer
Surgical wound
Other chronic ulcer or chronic wound
Other (specify):
Connective tissue disease
Obesity or morbid obesity
Pregnant
Urinary tract problems/abnormalities
Premature birth
Spina bifida

19. SUBSTANCE I G9 OTHER SUBSTANCES: (Check all that apply)
SMOKING: f7\ YW' U''h UHidd'ntL
ALCOHOL ABUSE:
DURING THE CURRENT HOSPITALIZATION, DID THE PATIENT RECEIVE MEDICATION ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER?
MARIJUANA, CANNABINOID (other than smoking)
OPIOID, DEA SCHEDULE I (e.g., heroin)
OPIOID, DEA SCHEDULE II-IV (e.g., methadone, oxycodone)
OPIOID, NOS
COCAINE
METHAMPHETAMINE
OTHER (specify):
UNKNOWN SUBSTANCE
DUD OR ABUSE
IDU
SKIN POPPING
NON-IDU
UNKNOWN

20. F-G7: 57 HCFG: f7\ YW' U''h UHidd'ntL
K 5 G-B7-89BHGD97-A9B7C @7H98' 'CF'ACF975 @B85F'
85 MG'5: H9F' <CGD-H5 @58A-GG-CB3
DF9J-CI G<CGD-H5 @N5HCB' B'H<9' M95F'69: CF9'8-G7:
IF YES, DATE OF DISCHARGE CLOSEST TO DISC:
OR, DATE UNKNOWN
FACILITY ID:
CJ9FB7 <HGH5M-B' @H7: 'B'H<9' M95F'69: CF9'8-G7:
CJ9FB7 <HGH5M-B' @H57 <'B'H<9' M95F'69: CF9'8-G7:
GI F; 9FM-B'H<9' M95F'69: CF9'8-G7:
71 FF9BH7 <FCB7' 8-5 @MG-G'
IF YES, TYPE:
IF HEMODIALYSIS, TYPE OF VASCULAR ACCESS:
AV fistula/graft
Hemodialysis central line
Unknown
PATIENT TRAVELED INTERNATIONALLY IN THE YEAR BEFORE DISC:
COUNTRY:
PATIENT HOSPITALIZED WHILE VISITING COUNTRY(IES) ABOVE:

&1U" K97 <H. lbs. oz. OR
&1V" <97 <H. ft. in. OR
&1W 6A= SSSSSSSS
Unknown
Unknown
Unknown



IFB971 @H F9G' CB@M &2" F97CF8 'H<9' 7C@BM7 CI BH.

IFB971 @H F9G'CB@M & . G= BG5B8 'GMADHCAG'5GGC7-5H98'K'H<'I F-B9'71 @H F9"

Please indicate if any of the following symptoms were reported during the 5 day time period including the 2 calendar days before through the 2 calendar days after the DISC.

- BcbY □ I\_b\_bck b □ Symptoms for patients ≤ 1 year of age only: □ Apnea □ Bradycardia □ Lethargy □ Vomiting □ Costovertebral angle pain or tenderness □ Frequency □ Suprapubic tenderness □ Urgency □ Dysuria □ Fever [temperature ≥ 100.4 °F (38 °C)]

&4U" =G5BH A7FC6-5 @I G9'fW'CF'CF5 @-B'H<9' '\$85MG'69: CF9'H<9'8-G7'8C7I A9BH983' □ Yes □ No □ Unknown

&4V" = 'M9GZ7 <97? '5 @@5BH A7FC6-5 @G' G98' -B'H<9' '\$85MG'69: CF9'H<9'8-G7. 'f\ YW'U''h UhUdd'nl'..... □ Unknown

- Amikacin □ Cefazolin □ Cefdinir □ Cefepime □ Cefiderocol □ Cefixime □ Cefotaxime □ Cefoxitin □ Cefpodoxime □ Ceftaroline □ Ceftriaxone □ Cefuroxime □ Cephalixin □ Ciprofloxacin □ Clarithromycin □ Clindamycin □ Dalbavancin □ Daptomycin □ Delafloxacin □ Doripenem □ Doxycycline □ Ertapenem □ Eravacycline □ Fidaxomicin □ Fosfomycin □ Gentamicin □ Imipenem/cilastatin □ Levofloxacin □ Linezolid □ Meropenem □ Meropenem/vaborbactam □ Metronidazole □ Moxifloxacin □ Nitrofurantoin □ Omadacycline □ Oritavancin □ Penicillin □ Piperacillin/tazobactam □ Polymyxin B □ Polymyxin E (colistin) □ Rifaximin □ Tedizolid □ Telavancin □ Tigecycline □ Tobramycin □ Trimethoprim □ Trimethoprim/sulfamethoxazole □ Vancomycin □ IV □ PO □ Other (specify): □ Other (specify):

REMINDER: Any prior antimicrobial use that is not noted above should be documented in the other (specify) field.

&5a" DID 'H<9' D5H9BH HAVE A POSITIVE TEST(S) FOR 'G5FGI7 cJ!& fA C@7I @F'5G65 MZG9FC@; MCF' CH<9F'7CB: -F A5HCFMH9GH'CB'CF' 69: CF9'H<9'8-G7'3'

&5b. IF YES, COMPLETE TABLE BELOW:

- Yes □ No □ Unknown

Table with 3 columns: Test description, Specimen collection date, Test type. Rows for 'FIRST positive test for SARS-CoV-2 on or before the DISC:' and 'MOST RECENT positive test for SARS-CoV-2 on or before the DISC:'.

&5W7 CJ-8 IB9H75 G9' -8.

&5X" BB8 GG'-8 g'fD@5 G9' DFCJ-89'5H'@5GH'CB9'C: 'H<9' : C@CK-B; 'K<9B'5DD@756@L

@W'cUgY'-8. @W'rYw'fX'-8. GHU'VUgY'X'YbHjZ'Yf. @[ U'w'vUgY'X'YbHjZ'Yf. CDC 2019-nCOV ID: \_\_\_\_\_

&6U"K 5 G'H<9' -B7-89BH GD97 -A9B' DC @MA-7FC6-5 @

&6c" IF TESTED, WHAT TESTING METHOD WAS USED3 (Check all that apply):'

&6d" IF TESTED, WHAT WAS THE RESULT:'

- Yes □ No □ Unknown

26b. WAS THE INCIDENT SPECIMEN TESTED FOR ESBL PRODUCTION OR OTHER BETA-LACTAMASE GENES?

- Broth Microdilution (ATi detection) □ ESBL well □ Expert rule (ATi flag) □ Unknown □ Broth Microdilution (Manual) □ Disk Diffusion □ E-test □ Molecular test (specify): □ Gene variant (specify): □ Other non-molecular test (specify):

- Positive □ Negative □ Indeterminate □ Unknown □ Positive □ Negative □ Indeterminate □ Unknown □ Positive □ Negative □ Indeterminate □ Unknown □ Positive □ Negative □ Indeterminate □ Unknown □ Positive □ Negative □ Indeterminate □ Unknown □ Positive □ Negative □ Indeterminate □ Unknown □ Positive □ Negative □ Indeterminate □ Unknown

- Yes □ No □ Laboratory not testing □ Unknown



2+ "GI G7 9DH6 =GHMF9GI @HG.

Please complete the table below based on the information found in the indicated data source. Shaded antibiotics are required to have the MIC entered into the MuGSI-CM system, if available

8 UH Gci fVW	Medical Record		Microscan		Vitek		Phoenix		Sensititre		Kirby-Bauer		E-test	
5 bhjVchjW	A 7	... bhfd	A 7	... bhfd	A 7	... bhfd	A 7	... bhfd	MIC	Interp	Zone Diam	Interp	MIC	Interp
5 a ]_UWj b														
5 a cl jW j b#` Uj i `UbUH Y														
5 a d jW j b														
5 a d jW j b#Gi `VUWUa														
5 nf YcbUa														
7 YZJnc` j b														
7 9: 9D=A9														
7 YZXYfcVc`														
7 9: CH5 L=A9														
7 YZ: I j j b														
7 9: H5 N8=A9														
7 YZUjXja Y# j jVUWUa														
7 YZc` cnUbY#HuncVUWUa														
7 9: HF=5 LCB9														
7 Yd\ Uch j b														
7 jdfcZcl Uj b														
7 C @GH=B														
8 CF=D9B9A														
8 cl nWwVj bY														
9 fUj UWwVj bY														
9 FH5 D9B9A														
: cgZ: a nVj b														
; YbHLa jVj b														
=A=D9B9A														
=a j dYbYa !fY VUWUa														
@j cZcl Uj b														
A9 FCD9B9A														
A YfcdYbYa !j UVcfVUWUa														
A jbc WwVj bY														
B jfcZ fUhc j b														
Ca UXUWwVj bY														
D j dYf Uj j b#HuncVUWUa														
D Unca jVj b														
DC @MML-B`6														
F jZLa d j b														
HYf UWwVj bY														
H; 97 M7 @B9														
Hc VfLa nVj b														
Trimethoprim-sulfamethoxazole														

28a. WAS CASE FIRST IDENTIFIED THROUGH AUDIT?  Yes  No

28b. CRF STATUS:  Complete  Pending  Chart unavailable after 3 requests

28c. SO INITIALS: \_\_\_\_\_

28d. DATE OF ABSTRACTION: \_\_\_\_\_

28e. COMMENTS: \_\_\_\_\_